News

Partner companies' news

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
Acorn Management Partners, Administrator
— April 2022 — 423 views PCSA

SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics [1] ( Nasdaq: SABS [2] ), (SAB), a clinical-stage biopharmaceutical compan...
Acorn Management Partners, Administrator
— April 2022 — 461 views SABS

Foresight Announces Fourth Quarter and Full Year 2021 Financial Results
--News Direct-- Foresight Autonomous Holdings Ltd., an innovator in automotive vision systems (Nasdaq and TASE: FRSX) (“Foresight”), today reported ...
Acorn Management Partners, Administrator
— April 2022 — 440 views FRSX

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage compa...
Acorn Management Partners, Administrator
— April 2022 — 427 views PCSA

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
SIOUX FALLS, S.D., March 29, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics [1] ( Nasdaq: SABS [2] ), (SAB), a clinical-stage biopharmaceutical compa...
Acorn Management Partners, Administrator
— April 2022 — 419 views SABS

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...
Acorn Management Partners, Administrator
— March 2022 — 420 views PCSA

Foresight to Present and Participate in a Panel Discussion at the Maxim Group Virtual Growth Conference
--News Direct-- *Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”)*,* *an innovator in automotive vision sys...
Acorn Management Partners, Administrator
— March 2022 — 460 views FRSX

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
Acorn Management Partners, Administrator
— March 2022 — 438 views PCSA

Medexus to Participate in the 34th Annual Roth Conference
TORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleas...
Acorn Management Partners, Administrator
— March 2022 — 486 views MEDXF

Medexus Pharmaceuticals Announces Deal for Gleolan in the United States
TORONTO and CHICAGO, March 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (*Medexus*) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it...
Acorn Management Partners, Administrator
— March 2022 — 454 views MEDXF

Foresight’s Technology to Replace Use of LiDAR by a Leading Israeli Defense Integrator for the Israeli Defense Forces
--News Direct-- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision systems...
Acorn Management Partners, Administrator
— February 2022 — 462 views FRSX

Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
TORONTO and CHICAGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (*Medexus*) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the...
Acorn Management Partners, Administrator
— February 2022 — 451 views MEDXF

Foresight: Eye-Net Selected by Paris2Connect Consortium to Participate in an Urban Mobility Experiment, Consortium Members Include Nokia, ATC France, Aximum, RATP Group and Signify
--News Direct-- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that its whol...
Acorn Management Partners, Administrator
— February 2022 — 424 views FRSX

Foresight Collaborates with a Leading Tier One Supplier on Enhancing ADAS Vision Systems
(via NewsDirect) Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision system...
Acorn Management Partners, Administrator
— February 2022 — 502 views FRSX

Foresight and SUNWAY-AI Collaborate to Commercialize Autonomous Technologies to the Chinese Agriculture Market
--News Direct-- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight”), an innovator in automotive vision systems, announced today...
Acorn Management Partners, Administrator
— January 2022 — 425 views FRSX

Foresight: Eye-Net Enters Indian Market with Pilot Project for Fleet Telematics
--News Direct-- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that its whol...
Acorn Management Partners, Administrator
— January 2022 — 492 views FRSX

Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 454 views ARTH

Foresight Expands Chinese Market Presence with Establishment of Local Subsidiary
--News Direct-- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), (“Foresight” or the “Company”), an innovator in automotive vision system...
Acorn Management Partners, Administrator
— January 2022 — 561 views FRSX

Arch Therapeutics Announces Appointment of Guy Fish to the Board
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 539 views ARTH

Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— December 2021 — 510 views ARTH

About us

Helping America invest in you:

Connecting your company stock with professional market participants.

One call at a time

Stay updated :

Participate on our social stream.

Our Blogs

Tags

Archives